Table 1.
Baseline demographics
| Characteristic | n=38 |
|---|---|
| Age (years) | 54 ± 13.5 |
| Sex (male, %) | 23 (60.5%) |
| Race, n (%) | |
| Caucasian | 36 (94.7%) |
| African American | 2 (5.3%) |
| Diagnoses (n, %) | |
| Glioblastoma multiforme | 21 (55.3%) |
| Anaplastic astrocytoma | 2 (5.3%) |
| Low grade astrocytoma | 4 (10.5%) |
| Pontine glioma | 1 (2.6%) |
| High-grade oligodendroglioma | 1 (2.6%) |
| Low-grade oligodendroglioma | 1 (2.6%) |
| High-grade mixed glioma | 2 (5.3%) |
| Primary central nervous system lymphoma | 6 (15.8%) |
| Glucocorticoids (n, %) | 20 (52.6%) |
| Prednisone | 3 (15%) |
| Dexamethasone | 17 (85%) |
| Chemotherapy (n, %) | 25 (65.8%) |
| 5-day temozolomide | 13 (52%) |
| 21-day temozolomide | 2 (8.0%) |
| Bevacizumab | 3 (12.0%) |
| Cilengitide | 1 (4.0%) |
| IMC-3G3 | 1 (4.0%) |
| Temozolomide, bevacizumab | 1 (4.0%) |
| Temozolomide, cilengitide | 3 (12.0%) |
| Methotrexate, rituximab | 1 (4.0%) |
| Radiation (n, %) | 3 (7.9%) |
Baseline demographics for the population including patients actively receiving glucocorticoids, chemotherapeutic agents, or radiation at the time of or within 1 week of vaccine administration.